We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
+2.62%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$1.87B
AUM Growth
-$718M
(-28%)
Cap. Flow
-$858M
Cap. Flow
% of AUM
-45.75%
Top 10 Holdings %
Top 10 Hldgs %
41.84%
Holding
112
New
12
Increased
13
Reduced
41
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Glaukos
GKOS
|
+$30.8M |
| 2 |
XENT
Intersect ENT, Inc
XENT
|
+$26.9M |
| 3 |
MNK
MALLINCKRODT PUBLIC LIMITED COMPANY
MNK
|
+$19.7M |
| 4 |
PDCO
Patterson Companies, Inc.
PDCO
|
+$17.7M |
| 5 |
McKesson
MCK
|
+$13.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BPMC
Blueprint Medicines
BPMC
|
+$49.3M |
| 2 |
Elevance Health
ELV
|
+$43.6M |
| 3 |
PTLA
Portola Pharmaceuticals, Inc.
PTLA
|
+$41.3M |
| 4 |
DBVT
DBV Technologies
DBVT
|
+$36.8M |
| 5 |
Centene
CNC
|
+$36.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 71.91% |
| 2 | Financials | 1.75% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
DexCom
DXCM
$29.6B
| $18.1M | 0.97% |
991,364
+547,396
| +123% | +$10.1M |
|
|
OXFD
27
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $15.9M | 0.85% |
945,710
+329,202
| +53% | +$4.92M |
|
|
AAAP
28
DELISTED
Advanced Accelerator Applications S.A.
AAAP
| $15.3M | 0.82% |
392,904
-130,119
| -25% | -$4.9M |
|
|
LKFT
29
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.97B
| $14.3M | 0.77% |
187,501
-72,267
| -28% | -$6.08M |
|
|
30
Elevance Health
ELV
$80.9B
| $14.1M | 0.75% |
75,182
-242,818
| -76% | -$43.6M |
|
31
Wave Life Sciences
WVE
$1.12B
| $13.9M | 0.74% |
746,841
+274,717
| +58% | +$5.92M |
|
|
AAC
32
DELISTED
AAC Holdings
AAC
| $13.7M | 0.73% |
1,975,347
| – | – |
|
|
SCTL
33
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
| $13.4M | 0.71% |
2,120,379
-193,246
| -8% | -$1.32M |
|
34
AnaptysBio
ANAB
$1.72B
| $13.2M | 0.71% |
552,859
-292,887
| -35% | -$7.36M |
|
35
eHealth
EHTH
$47.3M
| $13M | 0.69% |
690,348
-1,950,261
| -74% | -$31.1M |
|
36
Xencor
XNCR
$1.3B
| $11.9M | 0.63% |
562,236
-722,522
| -56% | -$16.2M |
|
37
CytomX Therapeutics
CTMX
$788M
| $11.7M | 0.63% |
756,822
-186,611
| -20% | -$2.81M |
|
38
Ascendis Pharma A/S
ASND
$17.1B
| $11.6M | 0.62% |
419,453
-509,773
| -55% | -$13.5M |
|
39
Ardelyx
ARDX
$1.28B
| $11.6M | 0.62% |
2,279,780
+1,438,036
| +171% | +$12.2M |
|
40
Axogen
AXGN
$2.12B
| $11.3M | 0.6% |
674,428
-1,163,797
| -63% | -$15.7M |
|
41
argenx
ARGX
$53.8B
| $10.8M | 0.58% |
+509,022
| New | +$10.6M |
|
|
NEOS
42
DELISTED
Neos Therapeutics, Inc
NEOS
| $10.7M | 0.57% |
1,459,195
-639,971
| -30% | -$4.83M |
|
43
Molina Healthcare
MOH
$11.7B
| $10.5M | 0.56% |
+151,665
| New | +$9.31M |
|
|
BPMC
44
DELISTED
Blueprint Medicines
BPMC
| $10.3M | 0.55% |
203,000
-1,162,000
| -85% | -$49.3M |
|
45
Aclaris Therapeutics
ACRS
$793M
| $10.2M | 0.54% |
375,000
| – | – |
|
|
EPZM
46
DELISTED
Epizyme, Inc
EPZM
| $10M | 0.53% |
662,369
-751,227
| -53% | -$11.4M |
|
|
SGMO
47
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $9.63M | 0.51% |
1,094,305
+256,342
| +31% | +$1.64M |
|
|
48
Centene
CNC
$32.8B
| $9.51M | 0.51% |
238,000
-969,286
| -80% | -$36.6M |
|
49
PUT
Puma Biotechnology
PBYI
$434M
| $9.09M | 0.48% |
+104,000
| New | +$5.82M |
|
|
STDY
50
DELISTED
SteadyMed Ltd
STDY
| $9.08M | 0.48% |
1,441,913
-314,457
| -18% | -$2.14M |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q2 2017 Portfolio in Review
As of Q2 2017, Deerfield Management held 112 positions worth $1.87B, down 28% from $2.59B the previous quarter. Its ten largest holdings account for 42% of the portfolio.
Deerfield Management withdrew a net $858M in Q2 2017, closing 27 positions and reducing 41 holdings. Its most notable exit was Vanda Pharmaceuticals, an estimated $32.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 72% of assets, up from 71% a quarter earlier, followed by Financials.
Against the trend, Deerfield Management opened a new position in Intersect ENT, Inc worth $33.2M.
- Deerfield Management's largest Q2 2017 buy was Intersect ENT, Inc: 1,189,577 shares worth $33.2M.
- Deerfield Management added most to Glaukos in Q2 2017, an estimated $30.8M increase.
- Deerfield Management's biggest Q2 2017 reduction was Blueprint Medicines, cutting an estimated $49.3M.
- Deerfield Management fully exited Vanda Pharmaceuticals in Q2 2017, selling an estimated $32.2M.
- Deerfield Management's ten largest holdings make up 42% of its $1.87B portfolio in Q2 2017.
- Deerfield Management opened 12 new positions and closed 27 in Q2 2017.
- Deerfield Management's portfolio value fell 28% quarter-over-quarter to $1.87B.
Based on Deerfield Management's 13F filing for Q2 2017, filed 14 Aug 2017.